Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company.
Sanofi has made another investment in artificial intelligence, taking a $180 million equity stake in Franco-US startup Owkin with another $90 million in funding for a program to seek out ne
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’
Exscientia's artificial intelligence-based drug discovery engine is still largely unproven, but that hasn't stopped the company raking in funding from investors keen to back its platform.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.